Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This study found that polymeric micelle formulations significantly improved the targeted delivery of adapalene to hair follicles compared to standard Differin® products, which suggests potential advantages in treating hair follicle-related conditions and reducing side effects.

This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.

This review reports that biopolymer-based hydrogels show promise as wound dressings due to their biocompatibility, moisture retention, and ability to mimic the extracellular matrix, though challenges in mass production, safety, and clinical validation remain.

This review highlights that Wedelolactone, a compound in Eclipta prostrata, appears to be a potent antioxidant and selective modulator of proteins linked to chronic diseases, suggesting further research into its pharmacological effects is warranted according to the examined data.

In a mouse model, this study reported that the compound isoalantolactone significantly improved hair growth and thickness, suggesting its potential as a treatment for hair loss.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

This study reported that a novel bilayer wound dressing made from PLCL nanofibers and keratin hydrogel, loaded with FGF-2, promoted skin healing and showed potential for use in skin tissue engineering.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This overview discusses primary cicatricial alopecias, focusing on lichen planopilaris, and highlights the challenges in treatment and the progressive nature of hair loss despite symptom management, without providing new clinical results.

This article reviews non-biodegradable progestational subdermal implants as long-acting contraceptives for women, discussing their effectiveness, associated side effects, and implementation challenges without reporting new clinical results.

This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well.

The study found that prolactin expressed in human scalp hair follicles acts as an autocrine modulator, inhibiting hair growth and promoting hair follicle regression, which may contribute to hair loss in hyper-prolactinemia patients.

This case report describes a 45-year-old man with a pituitary macroadenoma whose symptoms and tumor size improved significantly after one month of treatment with cabergoline.

This study developed cilostazol-loaded formulations for nose-to-brain delivery, finding that these formulations improved cilostazol's bioavailability by enhancing solubility, absorption, and permeability, achieving nearly 100% drug release in vitro within 2 hours.

Latanoprost eye drops caused excessive cheek hair growth and eyelash whitening in a woman.

This review explores contraceptive options for women with polycystic ovary syndrome, emphasizing the need for tailored choices based on individual clinical, hormonal, and metabolic profiles, but reports no new clinical findings.

This study evaluated a new anti-baldness product, IPSTiC patch hair, designed to treat androgenetic alopecia, and reported that it effectively inhibits NO radical and 5α-reductase activity while maintaining safety and stability, suggesting its potential for topical use.

This study found that paclitaxel poliglumex showed limited effectiveness and was relatively well tolerated in post-menopausal women with advanced NSCLC, suggesting further testing of this treatment may not be justified.

This research reported that a newly developed dually crosslinked gelatin-alginate-based hydrogel scaffold enhances mechanical strength, promotes corneal tissue regeneration, and reduces scarring in rabbit models, suggesting potential applications in corneal tissue engineering.

This report presents no new clinical results; it discusses the application of ACell MatriStem™, a porcine urinary bladder-derived extracellular matrix, in wound healing.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

This study observed that both polynucleotides (PN HPT™) and platelet-rich plasma (PRP) improved hair density and quality in men with androgenetic alopecia, with comparable outcomes and no significant adverse events.

This study identified orally available itaconate derivatives that improve cellular permeability and bioavailability, with specific POC-based prodrugs showing significant inhibition of inflammatory cytokines in human epidermal keratinocytes and favorable oral pharmacokinetics, highlighting their potential for treating systemic and skin disorders.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This review discusses prolactin production and regulation in human skin and hair follicles, highlighting its potential broader implications but reports no new empirical results.

This report describes a case of granulomatous reaction to injectable poly-L-lactic acid in the periorbital area and suggests surgical excision as an effective treatment for persistent nodules.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This article discusses platelet-rich plasma therapy for cicatricial alopecias like lichen planopilaris and reports no confirmed new clinical results; the authors highlight ongoing uncertainty about its effectiveness and potential risks.